LMR Partners’s Nektar Therapeutics NKTR Stock Holding History

LMR Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.08M	Buy	+130,000	New	+$9.51M	0.03%	449

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's NKTR Position: Q2 2026 in Review

LMR Partners increased its Nektar Therapeutics (NKTR) stake by 107% in Q2 2026, buying an estimated $3.78M and bringing the position to 100,000 shares worth $6.98M. The position accounts for 0.03% of the portfolio, ranked #543.

LMR Partners first reported a position in NKTR in Q2 2018 and has held it in 7 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

LMR Partners held 100,000 shares of Nektar Therapeutics worth $6.98M as of Q2 2026.
LMR Partners bought 51,706 Nektar Therapeutics shares in Q2 2026, an estimated $3.78M.
Nektar Therapeutics made up 0.03% of LMR Partners's portfolio in Q2 2026, its #543 holding.
LMR Partners first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 7 quarters since.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.